Compounds > 6-hydroxywarfarin
Page last updated: 2024-11-13

6-hydroxywarfarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-hydroxywarfarin: metabolite of (R)-warfarin; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54682459
CHEMBL ID148730
SCHEMBL ID1478281
MeSH IDM0051658

Synonyms (33)

Synonym
warfarin-alcohol
NCGC00165929-01
CHEMBL148730
6-hydroxywarfarin
SCHEMBL1478281
A812359
17834-02-5
2,6-dihydroxy-3-(3-oxo-1-phenyl-butyl)chromen-4-one
4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)-2h-1-benzopyran-2-one
p25d26m0hk ,
unii-p25d26m0hk
6-hydroxy warfarin
FT-0637611
2h-1-benzopyran-2-one,4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)-
6-hydroxywarfarin, (rs)-
6-hydroxywarfarin, (+/-)-
JFCOGWFGPAUYNK-UHFFFAOYSA-N
3-(.alpha.-acetonylbenzyl)-4,6-dihydroxycoumarin
2h-1-benzopyran-2-one, 4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)-
AKOS030239603
J-011369
6-monohydroxywarfarin
(r)-6-hydroxy warfarin
(s)-6-hydroxy warfarin
FT-0670233
4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)-2h-chromen-2-one
2,6-dihydroxy-3-(3-oxo-1-phenylbutyl)-4h-1-benzopyran-4-one
DTXSID50939073
Q27286027
6-hydroxywarfarin-d5
4,6-dihydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
PD039352
AKOS040755432

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"To develop population pharmacokinetic models of both R- and S-warfarin using clinical and genetic factors and to identify the covariates which influence the interindividual variability in the pharmacokinetic parameters of clearance and volume of distribution in patients on long-term warfarin therapy."( The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.
Aarons, L; Al-Zubiedi, S; Daly, AK; Deloukas, P; Hatch, E; Hughes, D; Jorgensen, AL; Kamali, F; Lane, S; Matthews, I; Ogungbenro, K; Park, BK; Pirmohamed, M, 2012)		0.38
" A base pharmacokinetic model was developed using NONMEM software to determine the warfarin clearance and volume of distribution."( The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.
Aarons, L; Al-Zubiedi, S; Daly, AK; Deloukas, P; Hatch, E; Hughes, D; Jorgensen, AL; Kamali, F; Lane, S; Matthews, I; Ogungbenro, K; Park, BK; Pirmohamed, M, 2012)		0.38

Dosage Studied

ExcerptRelevanceReference
"Warfarin is a drug with a narrow therapeutic index and large interindividual variability in daily dosing requirements."( The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.
Aarons, L; Al-Zubiedi, S; Daly, AK; Deloukas, P; Hatch, E; Hughes, D; Jorgensen, AL; Kamali, F; Lane, S; Matthews, I; Ogungbenro, K; Park, BK; Pirmohamed, M, 2012)		0.38
"Our analysis, based on exposure rather than dose, provides quantitative estimates of the clinical and genetic factors impacting on the clearance of both the S- and R-enantiomers of warfarin, which can be used in developing improved dosing algorithms."( The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.
Aarons, L; Al-Zubiedi, S; Daly, AK; Deloukas, P; Hatch, E; Hughes, D; Jorgensen, AL; Kamali, F; Lane, S; Matthews, I; Ogungbenro, K; Park, BK; Pirmohamed, M, 2012)		0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID293981Inhibition of rat microsomal VKER2007Bioorganic & medicinal chemistry, Mar-15, Volume: 15, Issue:6
Synthesis and structure-activity relationships of novel warfarin derivatives.
AID16339Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16344Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16342Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16341Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16340Amount of deuterium retained was reported after normal workup in rats1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
AID16345Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (16.67)18.7374
1990's3 (25.00)18.2507
2000's3 (25.00)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.94 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
hydroxymethyltolbutamide
hydroxymethyltolbutamide: tolbutamide metabolite. 4-hydroxytolbutamide : A urea that consists of 1-butylurea having a 4-hydroxymethylbenzenesulfonyl group attached at the 3-position.		1.9810benzyl alcohols;
sulfonamide;
ureas		metabolite
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		1.9510pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		1.9810N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		2.0410amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		1.9910dihydrogen
dicumarol
Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.		2.0310hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
acenocoumarol
Acenocoumarol: A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233). acenocoumarol : A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group.		2.0310C-nitro compound;
hydroxycoumarin;
methyl ketone		anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		3.8110benzenes;
hydroxycoumarin;
methyl ketone
ferulenol
ferulenol: intoxicating component of powdered Ferula communis variety brevifolia; RN given for (E,E)-isomer		2.0310
bromfenacoum
[no description available]		2.0310benzenes;
naphthalenes;
ring assembly
phenprocoumon
Phenprocoumon: Coumarin derivative that acts as a long acting oral anticoagulant.. phenprocoumon : A hydroxycoumarin that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenylpropyl group.		2.0310hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor
4'-hydroxywarfarin
4'-hydroxywarfarin: metabolite of warfarin; RN given refers to cpd without isomeric designation; structure given in first source		2.730hydroxycoumarin
7-hydroxywarfarin
7-hydroxywarfarin: a warfarin metabolite		3.71100hydroxycoumarin
10-hydroxywarfarin
10-hydroxywarfarin: structure given in first source		2.4420hydroxycoumarin
8-hydroxywarfarin
8-hydroxywarfarin: metabolic marker for (S)-mephenytoin hydroxylase (P4502C19); structure in first source		3.1250
ConditionIndicatedRelationship StrengthStudiesTrials
Thromboembolism
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.		02.0210
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		01.9810